effects of intra-ovarian injection of autologous platelet rich plasma

effects of intra-ovarian injection of autologous platelet rich plasma to ovarian reserve in poor responders

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101227005485N9

Enrollment

Registered

2021-01-22

Start date

2020-04-18

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diminished ovarian reserve. infertility due to diminished ovarian reserve

Interventions

Intervention 1: Intervention group: Immediately after second ovarian puncture, intra-ovarian injection of 2 millilitre of platelet-rich plasma into each ovary will be done. Platelet-rich plasma is tak

Eligibility

Sex/Gender

Female

Age

30 Years to 43 Years

Inclusion criteria

Inclusion criteria: Antimullerian hormone(AMH) less than 1.1 number of antral follicles less than 5-7 history of cycle cancellation due to insufficient follicular growth history of cycle cancellation due to less than 3 oocytes obtained willingness to cooperate Ages between 30 and 43 years

Exclusion criteria

Exclusion criteria: Immunoglobulin A deficiency genital or non-genital cancers treatment with anticoagulants ovarian failure due to chromosomal abnormality severe pelvic adhesion non-acceptance or cooperation of the patient

Design outcomes

Primary

Measure	Time frame
Number of oocytes obtained. Timepoint: Immediately after ovarian puncture before and 2 months after injection of platelet-rich plasma (PRP). Method of measurement: Under a microscope by an embryologist.;Follicular Stimulating Hormone (FSH) and Luteinizing Hormone (LH) day two or three of menstruation. Timepoint: Cycle before and 2 months after injection of platelet-rich plasma. Method of measurement: electrochemiluminescence.;Antimulerian hormone. Timepoint: Cycle before and 2 months after injection of platelet-rich plasma. Method of measurement: electrochemiluminescence.;Comparison of serum estradiol levels on the day of ovulation triggering. Timepoint: Cycle before and 2 months after injection of platelet-rich plasma. Method of measurement: electrochemiluminescence.	—

Measure

Time frame

Number of oocytes obtained. Timepoint: Immediately after ovarian puncture before and 2 months after injection of platelet-rich plasma (PRP). Method of measurement: Under a microscope by an embryologist.;Follicular Stimulating Hormone (FSH) and Luteinizing Hormone (LH) day two or three of menstruation. Timepoint: Cycle before and 2 months after injection of platelet-rich plasma. Method of measurement: electrochemiluminescence.;Antimulerian hormone. Timepoint: Cycle before and 2 months after injection of platelet-rich plasma. Method of measurement: electrochemiluminescence.;Comparison of serum estradiol levels on the day of ovulation triggering. Timepoint: Cycle before and 2 months after injection of platelet-rich plasma. Method of measurement: electrochemiluminescence.

—

Secondary

Measure	Time frame
Number of 4 to 8 cells embryos. Timepoint: 2 to 3 days. Method of measurement: With a microscope by an embryologist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazli Navali

Tabriz University of Medical Sciences

navalin@tbzmed.ac.ir+98 41 3554 1221

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026